deltatrials
Completed PHASE3 NCT00214630

LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes

A 12-week Randomized, Open-label 3-arm, Parallel Group, Multicenter Phase IIIb Study Comparing Efficacy and Safety of Rosuvastatin 20mg and 40mg With That of Atorvastatin 80 mg in Subjects With Acute Coronary Syndromes

Sponsor: AstraZeneca

Conditions Acute Coronary Syndromes
Interventions atorvastatin rosuvastatin calcium
Updated 6 times since 2017 Last updated: Nov 18, 2010 Started: Dec 31, 2003 Primary completion: Aug 31, 2007 Completion: Aug 31, 2007

A PHASE3 clinical study on Acute Coronary Syndromes, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2003. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Amarillo, United States, Anderson, United States, Ann Arbor, United States, Annapolis, United States, Asheville, United States, Atlantis, United States, Aurora, United States, Ayer, Morocco, Beaumont, United States and 46 more location s